2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenReally looking forward to the new CFO starting in September. Then it will be a good match with 3 women in top management with good experience in their respective areas. They most often have good intuition and know how to sell the company to big pharma companies. Uppsala, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as the new Chief Financial Officer (CFO). She will assume the position on September 1 and will then succeed Björn Petersson, who has been engaged on a consultancy basis. Cecilia Driving has long and broad experience as CFO and particularly deep knowledge of capital market issues, investor relations, and business development from leading positions in companies in clinical and commercial development phases. Cecilia Driving most recently comes from the role as CFO at the defense and technology company W5 Solutions, where she, among other things, led the financing of an acquisition. Prior to that, Cecilia was CFO at Mabtech Holding, where she ran a dual-track process that led to a sale to EQT. Cecilia has also been Executive Vice President, CFO, and Head of HR and IR at Biovica International, CFO and Managing Director at RISE (Research Institutes of Sweden), and has held CFO and legal roles at, among others, MedCap and Diamyd Medical. She has board experience from, among others, Ovzon and Embracer Group. "We are very pleased to welcome Cecilia Driving to Dicot Pharma. Her solid experience in capital market issues, investor relations, and business development in life science companies makes her a perfect match for us in the phase we are currently in. At the same time, I want to extend a big and warm thank you to Björn Petersson, whose efforts have been very valuable to the company during the just over four years he has held the CFO role," says Elin Trampe, CEO at Dicot Pharma.- ·9 t sittenI believe Citadel and others with short positions will now struggle to buy back shares without significantly raising the price. The sales we have seen have mainly been them themselves to push the price down, while also contributing to some nervous shareholders selling off some shares. 29 mill. visible short over 0.5% and assumed equivalent hidden shares which will eventually be covered.
·9 t sittenThen we were rid of Short sellers Wonder if this gang will continue until May 27 or what is the point? Is Dicot the right stock for this? By the way, one sees that they are everywhere As usual, shareholders become neither impressed nor excited
·2 päivää sittenI think management should review the number of shares. A reverse stock split should be in place. 1:100 This would result in a more stable price for the share and the speculators would get a bit less room. Today (0,48%) they have almost 17 million shares to play with. After a split 167 000 .
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenReally looking forward to the new CFO starting in September. Then it will be a good match with 3 women in top management with good experience in their respective areas. They most often have good intuition and know how to sell the company to big pharma companies. Uppsala, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as the new Chief Financial Officer (CFO). She will assume the position on September 1 and will then succeed Björn Petersson, who has been engaged on a consultancy basis. Cecilia Driving has long and broad experience as CFO and particularly deep knowledge of capital market issues, investor relations, and business development from leading positions in companies in clinical and commercial development phases. Cecilia Driving most recently comes from the role as CFO at the defense and technology company W5 Solutions, where she, among other things, led the financing of an acquisition. Prior to that, Cecilia was CFO at Mabtech Holding, where she ran a dual-track process that led to a sale to EQT. Cecilia has also been Executive Vice President, CFO, and Head of HR and IR at Biovica International, CFO and Managing Director at RISE (Research Institutes of Sweden), and has held CFO and legal roles at, among others, MedCap and Diamyd Medical. She has board experience from, among others, Ovzon and Embracer Group. "We are very pleased to welcome Cecilia Driving to Dicot Pharma. Her solid experience in capital market issues, investor relations, and business development in life science companies makes her a perfect match for us in the phase we are currently in. At the same time, I want to extend a big and warm thank you to Björn Petersson, whose efforts have been very valuable to the company during the just over four years he has held the CFO role," says Elin Trampe, CEO at Dicot Pharma.
- ·9 t sittenI believe Citadel and others with short positions will now struggle to buy back shares without significantly raising the price. The sales we have seen have mainly been them themselves to push the price down, while also contributing to some nervous shareholders selling off some shares. 29 mill. visible short over 0.5% and assumed equivalent hidden shares which will eventually be covered.
- ·9 t sittenThen we were rid of Short sellers Wonder if this gang will continue until May 27 or what is the point? Is Dicot the right stock for this? By the way, one sees that they are everywhere As usual, shareholders become neither impressed nor excited
- ·2 päivää sittenI think management should review the number of shares. A reverse stock split should be in place. 1:100 This would result in a more stable price for the share and the speculators would get a bit less room. Today (0,48%) they have almost 17 million shares to play with. After a split 167 000 .
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenReally looking forward to the new CFO starting in September. Then it will be a good match with 3 women in top management with good experience in their respective areas. They most often have good intuition and know how to sell the company to big pharma companies. Uppsala, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as the new Chief Financial Officer (CFO). She will assume the position on September 1 and will then succeed Björn Petersson, who has been engaged on a consultancy basis. Cecilia Driving has long and broad experience as CFO and particularly deep knowledge of capital market issues, investor relations, and business development from leading positions in companies in clinical and commercial development phases. Cecilia Driving most recently comes from the role as CFO at the defense and technology company W5 Solutions, where she, among other things, led the financing of an acquisition. Prior to that, Cecilia was CFO at Mabtech Holding, where she ran a dual-track process that led to a sale to EQT. Cecilia has also been Executive Vice President, CFO, and Head of HR and IR at Biovica International, CFO and Managing Director at RISE (Research Institutes of Sweden), and has held CFO and legal roles at, among others, MedCap and Diamyd Medical. She has board experience from, among others, Ovzon and Embracer Group. "We are very pleased to welcome Cecilia Driving to Dicot Pharma. Her solid experience in capital market issues, investor relations, and business development in life science companies makes her a perfect match for us in the phase we are currently in. At the same time, I want to extend a big and warm thank you to Björn Petersson, whose efforts have been very valuable to the company during the just over four years he has held the CFO role," says Elin Trampe, CEO at Dicot Pharma.
- ·9 t sittenI believe Citadel and others with short positions will now struggle to buy back shares without significantly raising the price. The sales we have seen have mainly been them themselves to push the price down, while also contributing to some nervous shareholders selling off some shares. 29 mill. visible short over 0.5% and assumed equivalent hidden shares which will eventually be covered.
- ·9 t sittenThen we were rid of Short sellers Wonder if this gang will continue until May 27 or what is the point? Is Dicot the right stock for this? By the way, one sees that they are everywhere As usual, shareholders become neither impressed nor excited
- ·2 päivää sittenI think management should review the number of shares. A reverse stock split should be in place. 1:100 This would result in a more stable price for the share and the speculators would get a bit less room. Today (0,48%) they have almost 17 million shares to play with. After a split 167 000 .
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt